Japanese Firm Invests Rp539 Billion to Build Plasma Industry
The Ministry of Investment and Downstream Industry/BKPM has welcomed the investment commitment of Japanese biopharmaceutical company Takeda to develop the plasma-derived medicine industry in Indonesia. In the initial phase, the company will invest up to USD30 million, or around Rp539 billion, over two years.
The investment will be focused on building a plasma bank network as the foundation for developing the national plasma industry. The government considers this step capable of strengthening the high-tech health industry at home.
Minister of Investment and Downstream Industry/Head of BKPM, Rosan P. Roeslani, said Takeda’s investment demonstrates growing confidence among global investors in Indonesia. According to him, this confidence is particularly evident in the prospects for developing the high-tech health industry sector.
“This is a strategic investment that opens opportunities for technology transfer, human resource development, and the creation of highly skilled jobs. The government encourages investment that adds value and strengthens national industrial capacity,” Rosan said in a statement received by RRI on Tuesday, 14 July 2026.
According to Rosan, the cooperation aligns with the economic transformation agenda through downstreaming in strategic sectors, including health. The effort is expected to enhance the competitiveness of national industry while strengthening Indonesia’s position in the global supply chain.
BKPM noted that Japan remains one of Indonesia’s principal investment partners. In the first quarter of 2026, realised Japanese investment reached USD1 billion, placing it fifth among Indonesia’s largest investors.
Meanwhile, from 2021 through the first quarter of 2026, total realised Japanese investment reached USD18.1 billion. That investment grew at an average of 13.2 per cent and absorbed around 299,460 workers.
The government hopes this collaboration can improve public access to plasma-derived medicines while building a competitive biopharmaceutical industry ecosystem. The first plasma bank is targeted to begin operating in 2027, in accordance with international standards.
Source: jawawa.id (https://jawawa.id/newsitem/japanese-firm-invests-rp539-billion-to-build-plasma-industry-1784044227)
Originally published by rri.co.id (https://rri.co.id/nasional/2567101/perusahaan-jepang-investasi-rp539-miliar-bangun-industri-plasma), translated from Indonesian